Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19442326 | 0.87 | EGFR (0.45) | EGFRALDH1A1IGF1RKCNH2WDR5 | |
| SCHEMBL24726489 | 0.83 | EGFR (0.54) | EGFRUCHL3IGF1RKCNH2 | |
| SCHEMBL13832430 | 0.83 | SIRT6 (0.49) | SIRT6ALDH1A1WDR5 | |
| SCHEMBL31348830 | 0.82 | EGFR (0.53) | EGFRUCHL3IGF1RKCNH2 | |
| SCHEMBL16385655 | 0.82 | EGFR (0.53) | EGFRUCHL3IGF1RKCNH2 | |
| SCHEMBL21816616 | 0.81 | EGFR (0.59) | EGFRUCHL3IGF1RKCNH2 | |
| SCHEMBL28572522 | 0.80 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL21816701 | 0.80 | EGFR (0.54) | EGFRUCHL3IGF1RKCNH2 | |
| SCHEMBL23983216 | 0.80 | EGFR (0.55) | EGFRIGF1RKCNH2 | |
| SCHEMBL19221921 | 0.78 | EGFR (0.53) | EGFRIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180009782-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-9783524-B2 | Protein tyrosine kinase modulators and methods of use | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-05-26 | — | — | US | disclosed |
| WO-2015003658-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | BETTA PHARMACEUTICALS CO., LTD (CN) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145237-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | ALK, EGFR, ERBB2 | EGFR 2/4885SIRT6 3313/4885ALDH1A1 2546/4885 |
| US-20180009782-A1 | PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | ALK, EGFR, ERBB2 | EGFR 2/4885SIRT6 3313/4885ALDH1A1 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.